Company intelligence / Profile preview
Otsuka America Pharmaceutical
- Ownership
- Private
- Employees
- ~45000
- Development stage
- Other
Overview
Otsuka America Pharmaceutical (OAPI) markets multiple FDA-approved drugs—such as aripiprazole (ABILIFY), brexpiprazole (REXULTI), and tolvaptan (JYNARQUE)—for CNS and nephrology indications. Its development pipeline includes candidates in Phase 1-3 for CNS, nephrology, autoimmune diseases, metabolic disorders, and infectious diseases[2][6]. JNT-517 has achieved clinical proof of concept for PKU; other assets include new therapies for ALS, autoimmune kidney disorders, and TB.
- Therapeutic areas
- ImmunologyCardiovascularPsychiatryInfectious DiseasesMetabolic DisordersNephrologyNeurology
- Modalities
- Small moleculeAntibodyAntisense oligonucleotideBiologicMonoclonal antibody
- Industry
- Biotech
Drug pipeline
4 assets3 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Otsuka America Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Otsuka America Pharmaceutical.